Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.69 |
| ▸ | MMP13 | P45452 | 14/20 | 0.69 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.69 |
| ▸ | MMP7 | P09237 | 2/20 | 0.69 |
| ▸ | MMP12 | P39900 | 1/20 | 0.69 |
| ▸ | MMP14 | P50281 | 1/20 | 0.69 |
| ▸ | MMP9 | P14780 | 2/20 | 0.61 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610090 | 1.00 | MMP2 (0.69) | MMP2MMP13ADAMTS4MMP7MMP12 | |
| SCHEMBL3609427 | 0.88 | MMP2 (0.61) | MMP2MMP13ADAMTS4MMP7MMP12 | |
| SCHEMBL3609431 | 0.88 | MMP2 (0.61) | MMP2MMP13ADAMTS4MMP7MMP12 | |
| SCHEMBL3614348 | 0.87 | MMP2 (0.54) | MMP2MMP13ADAMTS4MMP7MMP12 | |
| SCHEMBL3614345 | 0.87 | MMP2 (0.54) | MMP2MMP13ADAMTS4MMP7MMP12 | |
| SCHEMBL3603714 | 0.86 | MMP13 (0.69) | MMP2MMP13ADAMTS4MMP7MMP12 | |
| SCHEMBL3603711 | 0.86 | MMP13 (0.69) | MMP2MMP13ADAMTS4MMP7MMP12 | |
| SCHEMBL3618624 | 0.82 | MMP2 (1.00) | MMP2MMP13ADAMTS4MMP7MMP12 | |
| SCHEMBL2382350 | 0.82 | MMP2 (1.00) | MMP2MMP13ADAMTS4MMP7MMP12 | |
| SCHEMBL3616920 | 0.82 | MMP2 (1.00) | MMP2MMP13ADAMTS4MMP7MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | claimed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | claimed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| CN-1623537-A | Biaryl sulfonamides and its using method | WYETH CORP (US) | 2005-06-08 | — | — | CN | claimed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | MMP2 106/4885MMP13 257/4885ADAMTS4 63/4885 |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | MMP2 5/4885MMP13 13/4885ADAMTS4 113/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | MMP2 5/4885MMP13 13/4885ADAMTS4 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.